Celularity Inc. (GXGX) |
| 10.2 2.18 (27.18%) 07-19 00:00 |
| Open: | 8.18 |
| High: | 12.58 |
| Low: | 8.07 |
| Volume: | 17,319,220 |
| Market Cap: | 1,479(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Shell Companies |
| Sector: | Financial Services |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 14.69 |
| Resistance 1: | 12.58 |
| Pivot price: | 9.94 |
| Support 1: | 9.58 |
| Support 2: | 7.73 |
| 52w High: | 13.4 |
| 52w Low: | 7.73 |
GX Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company is not engaged in any business operations and it has not generated any revenue.
Financials
| EPS | 0.000 |
| Book Value | 0.670 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -1.3 |
| Return on Equity (ttm) | 0.0 |
Company news
Mon, 15 May 2023
Genting-backed biotech firm to get new investor - The Edge Malaysia
Fri, 06 Aug 2021
Genting Bhd's biotech arm strikes cancer treatment research partnership with Australia-listed firm - The Edge Malaysia
Fri, 16 Jul 2021
Celularity, clinical-stage cellular medicine company, goes public following $138 million merger - Medical Economics
Thu, 08 Apr 2021
Kok Thay says Genting Bhd's medical R&D investments 'pose higher risks than other investments' - The Edge Malaysia
Fri, 15 Jan 2021
Healthcare Roundup - Norway says deaths after COVID-19 jab may be from side effects, Sorrento could nearly quadruple in value: analyst - NAI500
Sun, 10 Jan 2021
Genting unlocks value of life science division via potential listing of SPAC - The Edge Malaysia
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
